BC Platforms Closes USD $10 million Series B Financing

09.05.2017 08:02
Big data screen

BC Platforms is a big data company developing a platform with clinical and genomic data from 5 million subjects. The company headquartered in Basel announced that it has closed a US10 million financing round. , to transform drug development and bring clinical benefits to patients.

The round was led by Debiopharm Innovation Fund in conjunction with Tesi, a Finnish venture capital and private equity company, and was supported by BC Platforms’ existing investors. BC Platforms will use the funds to launch new technologies in 2017 integrating complex clinical and genomic data in order to deliver precision medicine and clinical patient benefits, as well as to grow its existing genomic data management software business worldwide.

To date, the company has established partnerships with over 50 enterprise level Healthcare units and biobanks globally in 19 countries representing more than 2 million subjects.

BC Platforms’ vision is to provide the world’s leading analytics platform for healthcare and industry, with access by 2020 to over 5 million subjects’ diverse genomic and clinical data and samples consolidated from a global network of biobanks. Biobanks are organized repositories of human biological material and associated data stored for research purposes. BC Platforms partners with biobanks to aggregate these data for analysis to provide transformative solutions for customers across all therapeutic areas and along the entire product development life cycle. BC Platforms has global operations with its headquarters in Basel, Switzerland, research and development located in Helsinki, Finland, and sales and marketing based in London, Boston, and Vancouver.

Tero Silvola, CEO at BC Platforms, said: ‘We are delighted to have been supported by Debiopharm Innovation Fund and Tesi in this new financing round. This funding will enable us to progress to our next stage of expansion and to launch our new knowledge based solutions for R&D customers worldwide. Debiopharm’s experience in drug development will provide us with invaluable insight as we launch this major new initiative.’

Tanja Dowe, Head of Debiopharm Innovation Fund, said: “We see big data as a core asset in research and development. We are excited to have invested in BC Platforms and look forward to working with them to unlock the potential of big data to dramatically improve R&D productivity and provide clinical benefits to patients. BC Platforms fits directly with our fund’s vision to invest in innovative companies that change the way we develop drugs and treat patients.

(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Please login or
register to use the
bookmark feature

Related tags

Read more about

Principal

23.06.2017
Editorial

One big innovation park

Partners

Contributors